RNA interference (RNAi) provides researchers with a versatile means to modulate target
gene expression. The major forms of RNAi molecules, genome-derived microRNAs …

Proprotein convertase subtilisin/kexin type 9 (PCSK9) has evolved as a pivotal enzyme in
lipid metabolism and a revolutionary therapeutic target for hypercholesterolemia and its …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for developing
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Dyslipidemia treatment is of major importance in reducing the risk of atherosclerotic
cardiovascular disease (ASCVD), which is still the most common cause of death worldwide …

The burden of atherosclerotic disease worldwide necessitates implementing the treatment of
its risk factors. Among them, hypercholesterolemia has a central role. In addition to …

Abstract Purpose of Review Plasma levels of LDL cholesterol (LDL-C) are causally
associated with cardiovascular risk. Reducing LDL-C results in a decreased incidence of …

Elevated low-density lipoprotein cholesterol (LDL-C) level is associated with an increased
risk of atherosclerotic cardiovascular disease. Although high-intensity lipid-lowering …

Transforming growth factor beta (TGFβ) is named for the function it was originally discovered
to perform-transformation of normal cells into aggressively growing malignant cells. It …

Inclisiran (Leqvio®) is a first-in-class, subcutaneously administered, small interfering RNA
(siRNA) that prevents hepatic synthesis of proprotein convertase subtilisin/kexin type 9 …

Introduction There are inconsistent findings regarding the effect of lipid-lowering agents on
nonalcoholic fatty liver disease (NAFLD). Proprotein Convertase Subtilisin/Kexin type 9 …